- Home
- TYRA vs NIE Comparison
TYRA vs NIE Comparison
Compare TYRA & NIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- NIE
- Stock Information
- Founded
- TYRA 2018
- NIE 2007
- Country
- TYRA United States
- NIE United States
- Employees
- TYRA N/A
- NIE N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- NIE Investment Managers
- Sector
- TYRA Health Care
- NIE Finance
- Exchange
- TYRA Nasdaq
- NIE Nasdaq
- Market Cap
- TYRA 576.6M
- NIE 660.9M
- IPO Year
- TYRA 2021
- NIE N/A
- Fundamental
- Price
- TYRA $10.47
- NIE $23.94
- Analyst Decision
- TYRA Strong Buy
- NIE
- Analyst Count
- TYRA 7
- NIE 0
- Target Price
- TYRA $30.86
- NIE N/A
- AVG Volume (30 Days)
- TYRA 364.1K
- NIE 70.5K
- Earning Date
- TYRA 08-06-2025
- NIE 01-01-0001
- Dividend Yield
- TYRA N/A
- NIE 9.04%
- EPS Growth
- TYRA N/A
- NIE N/A
- EPS
- TYRA N/A
- NIE N/A
- Revenue
- TYRA N/A
- NIE N/A
- Revenue This Year
- TYRA N/A
- NIE N/A
- Revenue Next Year
- TYRA N/A
- NIE N/A
- P/E Ratio
- TYRA N/A
- NIE N/A
- Revenue Growth
- TYRA N/A
- NIE N/A
- 52 Week Low
- TYRA $6.42
- NIE $18.61
- 52 Week High
- TYRA $29.60
- NIE $22.47
- Technical
- Relative Strength Index (RSI)
- TYRA 58.12
- NIE 62.81
- Support Level
- TYRA $9.93
- NIE $23.71
- Resistance Level
- TYRA $10.49
- NIE $24.05
- Average True Range (ATR)
- TYRA 0.59
- NIE 0.26
- MACD
- TYRA 0.08
- NIE 0.02
- Stochastic Oscillator
- TYRA 94.30
- NIE 89.59
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.